The investigational anti-amyloid drug donanemab significantly slowed cognitive and functional decline in a phase 3 study of adults with early symptomatic Alzheimer's disease, according to topline results hailed as highly encouraging by experts.
The investigational anti-amyloid drug donanemab significantly slowed cognitive and functional decline in a phase 3 study of adults with early symptomaticDonanemab met the primary endpoint, change from baseline until 18 months on the integrated Alzheimer's Disease Rating Scale , and all secondary endpoints measuring cognitive and functional decline, Eli Lilly saidIn the randomized, double-blind, placebo-controlled TRAILBLAZER-ALZ 2 trial, nearly half of patients taking donanemab had no...
"These are the strongest phase 3 data for an Alzheimer's treatment to date," Maria C. Carrillo, PhD, Alzheimer's Association chief science officer, said in a statement. The incidence of amyloid-related imaging abnormalities , a side effect of treatment, was consistent with the TRAILBLAZER-ALZ phase 2 study. The incidence of serious ARIA was 1.6%, including two participants whose death was attributed to ARIA and a third who died after an incident of serious ARIA.
"These are really encouraging results and show that targeting fundamental mechanisms in Alzheimer's can potentially make a difference to people's lives," said Malhotra.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Eli Lilly's Alzheimer's drug donanemab slows cognitive decline: trialAn experimental drug just showed it can help slow Alzheimer's, offering new hope for patients and a major boost to pharma giant Eli Lilly
Read more »
Eli Lilly Alzheimer’s treatment donanemab slowed disease progression in clinical trialDonanemab, a monthly antibody infusion made by pharmaceutical company Eli Lilly, also significantly reduced brain plaque associated with Alzheimer's disease.
Read more »
Experimental Drug Slows Alzheimer’s in Large Study, Eli Lilly SaysAn experimental Eli Lilly drug slowed cognitive and functional decline for people with early-stage Alzheimer’s disease in a new study that could support regulatory approval and commercial sale
Read more »
New Alzheimer's drug slows disease by a thirdThe second such drug in a year raises hopes we can start treating dementia.
Read more »
Lilly drug slows Alzheimer's progression by 35% in trialAn experimental Alzheimer's drug developed by Eli Lilly and Co slowed cognitive decline by 35% in a closely watched late-stage trial, the company said on Wednesday, raising hopes for a second effective treatment for the brain-wasting disease.
Read more »
Study: Experimental Alzheimer’s drug slows declineStudy: Experimental Alzheimer’s drug slows decline.
Read more »